Aclaris Therapeutics (NASDAQ:ACRS) Upgraded at Wall Street Zen

Aclaris Therapeutics (NASDAQ:ACRS) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other analysts have also commented on the company. Craig Hallum assumed coverage on Aclaris Therapeutics in a research note on Friday, January 30th. They issued a “buy” rating and a $10.00 price target on the stock. Wedbush reissued an “outperform” rating and set a $8.00 price objective on shares of Aclaris Therapeutics in a report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Friday, March 27th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of Aclaris Therapeutics in a report on Thursday, March 19th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.80.

Aclaris Therapeutics Price Performance

Shares of ACRS opened at $4.20 on Friday. The stock has a market cap of $506.52 million, a price-to-earnings ratio of -7.92 and a beta of 0.67. Aclaris Therapeutics has a 12 month low of $1.05 and a 12 month high of $4.89. The company has a 50-day moving average price of $3.48 and a two-hundred day moving average price of $2.89.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Thursday, February 26th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.01). Aclaris Therapeutics had a negative net margin of 829.58% and a negative return on equity of 52.04%. The company had revenue of $1.30 million during the quarter, compared to the consensus estimate of $2.07 million. Equities research analysts expect that Aclaris Therapeutics will post -0.82 EPS for the current fiscal year.

Institutional Investors Weigh In On Aclaris Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. R Squared Ltd bought a new position in shares of Aclaris Therapeutics in the fourth quarter worth about $37,000. AXQ Capital LP bought a new stake in shares of Aclaris Therapeutics during the third quarter valued at approximately $27,000. CIBC Asset Management Inc acquired a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at approximately $52,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at approximately $53,000. Finally, ProShare Advisors LLC raised its position in Aclaris Therapeutics by 45.4% in the 4th quarter. ProShare Advisors LLC now owns 21,553 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 6,734 shares during the last quarter. Institutional investors and hedge funds own 98.34% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.